Clinical trials: Oral Disorders
Diffuse Cutaneous Systemic Sclerosis
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).
- Trial name
- NCT04166552
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 36 people
- Sponsor
- Emerald Health Pharmaceuticals
Healthy
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered…
- Trial name
- NCT02412449
- Testing
- AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Dysphagia, Malnutrition
IDDSI Nutritional Drink for Dysphagia Study
This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.
- Trial name
- NCT03679078
- Testing
- IDDSI nutritional supplement drink
- Where
- 8 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Nutricia UK Ltd
Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2
The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with…
- Trial name
- NCT03452085
- Testing
- artificial saliva spray (AS), maritime throat spray (TT)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Certmedica International GmbH
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Dentin Sensitivity
Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief
The aim of this study is to evaluate the impact of a commercially available desensitizing dentifrice containing 5 percent (%) Calcium sodium phosphosilicate (CSPS) on oral health related quality of life (OHrQoL) in a DH (Dentin…
- Trial name
- NCT07300540
- Testing
- Calcium sodium phosphosilicate (CSPS) Toothpaste
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- HALEON
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Gastrointestinal Cancer, Biliary Tract Cancer
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI)…
- Trial name
- NCT03531320
- Testing
- D07001-softgel capsules
- Where
- 4 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- InnoPharmax Inc.
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
- Trial name
- NCT07644559
- Testing
- VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 185 people
- Sponsor
- Verastem, Inc.
Diabetes Mellitus, Type 2
Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers
The purpose of the study is to investigate the safety, tolerability, pharmacokinetics incl. dose proportionality, and pharmacodynamics of BI 135585 XX (Part 1), as well as the relative bioavailability of two different immediate…
- Trial name
- NCT01146886
- Testing
- BI 135585
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.
- Trial name
- NCT07634770
- Testing
- oral insulin, subcutaneous insulin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Drug-induced Tardive Dyskinesia
A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
This Phase 2 study was designed to evaluate the efficacy and safety of SNC-102 in subjects with drug-induced Tardive Dyskinesia (TD).
- Trial name
- NCT02064010
- Testing
- SNC-102
- Where
- United States
- Sponsor
- Synchroneuron Inc.
Healthy Volunteers, Asthma
Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals
RP3128 is a calcium release activated calcium (CRAC) channel modulator. The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending dose(s) of RP3128 in healthy…
- Trial name
- NCT02958982
- Testing
- RP3128
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Rhizen Pharmaceuticals SA
Hand, Foot and Mouth Disease
Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71
The purpose of this study is to evaluate the safety and immune response of an inactivated vaccine to prevent hand, foot and mouth disease (HFMD) caused by Enterovirus 71 (EV71).
- Trial name
- NCT01376479
- Testing
- INV21 Low Dose, INV21 High Dose
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Inviragen Inc.
Primary Myelofibrosis, Post-Polycythemia Vera
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
This study assessed the safety and efficacy of Panobinostat as a single agent in the treatment of Primary Myelofibrosis, Post-Polycythemia Vera and Post-Essential Thrombocythemia.
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
- Trial name
- NCT00931762
- Testing
- Panobinostat
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy.
- Trial name
- NCT01118962
- Testing
- Lacosamide
- Where
- 19 sites in United States
- Volunteers
- 39 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Hematopoietic Neoplasm
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 300 mg, 400 mg, and 500 mg SAR302503 for the reduction of spleen volume as determined by magnetic resonance imaging (MRI).
- Trial name
- NCT01420770
- Testing
- SAR302503
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
NASH - Nonalcoholic Steatohepatitis
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
This is a Phase 1, open-label, drug-drug interaction (DDI) study of pemvidutide (ALT-801) under steady state conditions on concomitantly administered medications in healthy subjects.
- Trial name
- NCT04972396
- Testing
- Pemvidutide, Metformin, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Type 2 Diabetes Mellitus
Insulin Glargine in Type 2 Diabetes Mellitus
Primary objective: To compare efficacy of oral antidiabetics (OAD) combination therapy with either HOE901 insulin analogue once daily or Lispro insulin analogue at mealtime in terms of change in HbA1c (baseline to endpoint).
- Trial name
- NCT00311818
- Testing
- Insulin glargine
- Sponsor
- Sanofi